Dopamine D2/D3 and serotonin 5-HT1A receptor

Assets acting on this target.

Class
Serotonin-dopamine activity modulator (antipsychotic)

Dopamine D2 and D3 receptors, along with the serotonin 5-HT1A receptor, belong to families of G-protein-coupled receptors that regulate mood, motivation, cognition, and movement across several brain circuits. In psychotic and mood disorders, dopamine signaling through D2/D3 receptors is thought to be excessive in some brain regions and insufficient in others, while serotonergic tone through 5-HT1A contributes to anxiety and mood regulation. Rather than simply blocking dopamine receptors, as older antipsychotics do, this mechanism uses partial agonism: the compound occupies D2/D3 receptors and produces a fraction of dopamine's own effect, effectively dampening signaling where dopamine is overactive while providing a baseline of stimulation where it is underactive. Combined partial agonism at 5-HT1A adds an anxiolytic and mood-stabilizing influence and can further modulate dopamine release in cortical regions. This dual receptor profile is used across schizophrenia, bipolar disorder, and as an adjunct in major depressive disorder, where the goal is to normalize dysregulated dopamine and serotonin activity rather than uniformly suppress it. The approach is intended to treat core symptoms while reducing the risk of certain movement-related and hormonal side effects associated with full dopamine receptor blockade.

By indication

Related mechanisms

Dopamine D2/D3 and serotonin 5-HT1A receptor drugs compared

6 drugs, stage by indication
6 drugs acting on Dopamine D2/D3 and serotonin 5-HT1A receptor: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
Aripiprazole (Abilify Maintena)Abilify MaintenaH. Lundbeck, Otsuka Holdingssmall moleculeApprovedApproved in Bipolar Disorder; Approved in Schizophrenia
Aripiprazole (Abilify)AbilifyH. Lundbeck, Otsuka Holdingssmall moleculeApprovedApproved in Bipolar Disorder; Approved in Major Depressive Disorder; Approved in Schizophrenia
Aripiprazole lauroxil (Aristada Initio)Aristada InitioAlkermes plcsmall molecule (long-acting injectable prodrug)ApprovedApproved in Schizophrenia
Aripiprazole lauroxil (Aristada)AristadaAlkermes plcsmall moleculeApprovedApproved in Schizophrenia
Brexpiprazole (Rexulti)RexultiH. Lundbeck, Otsuka Holdingssmall moleculeApprovedApproved in Major Depressive Disorder; Approved in Schizophrenia; Phase 3 in Alzheimer's Disease
Brexpiprazole long-acting injection (Kelun)Sichuan Kelun Pharmaceutical Co., Ltd.small moleculePhase 1Phase 1 in Schizophrenia

← all mechanisms